Table 2 |
||||||||
|
Studies examining efficacy or effectiveness of 19F-containing vaccines against 19A carriage |
||||||||
|
Study & location |
Vaccine |
Vaccine regimen |
Age group(s) sampled |
Number of Subjects |
Number of 19F isolates |
Efficacy against 19F VE or OR (95% CI or p value) |
Number of 19A isolates |
Efficacy against 19A VE or OR (95% CI or p value) |
|
|
||||||||
|
South Africa [42]: double blind, randomized, efficacy |
9vCRM |
6,10,14 wk |
9 mo |
242 (vacc) 239 (ctrl) |
19 (vacc) 32 (ctrl) |
VE 42%* (p = 0.05) |
7 (vacc) 11 (ctrl) |
VE 37%* (NS) |
|
|
||||||||
|
Israel [43]: double blind, randomized efficacy |
9vCRM |
12-24 mo received 2 doses; ≥ 24 mo 1 dose |
15-35 mo 36-≥ 48 mo |
816 (vacc) 790 (ctrl) 1071 (vacc) 1073 (ctrl) |
41 (vacc) 62 (ctrl) 57 (vacc) 52 (ctrl) |
OR 0.58 (p = 0.08) OR 1.11 (p = 0.69) |
n.a. = 113 total (all groups combined) |
OR 0.60** (p = 0.38) OR 1.25** (p = 0.56) |
|
|
||||||||
|
US Navajo Apache [21]: double blind, randomized efficacy |
7vCRM |
2,4,6,12-15 mo (87%) |
1-7 y (median 3.3y) All >12 mo since last dose |
468 (vacc) 281 (ctrl) |
24 (vacc) 16 (ctrl) |
OR 0.89 (0.47-1.72) |
12 (vacc) 10 (ctrl) |
OR 0.71 (0.30-1.67) |
|
|
||||||||
|
US Navajo Apache [23]: double blind, randomized efficacy |
7vCRM |
2,4,6,12-15 mo |
7 mo |
227 (vacc) 226 (ctrl) |
2 (vacc) 11 (ctrl) |
OR not calculated because "small sample size resulted in non-convergence of model" |
10 (vacc) 4 (ctrl) |
OR 1.75 (0.41-7.58) |
|
12 mo |
226 (vacc) 208 (ctrl) |
7 (vacc) 8 (ctrl) |
3 (vacc) 7 (ctrl) |
OR 0.38 (0.09-1.57) |
||||
|
18 mo |
239 (vacc) 219 (ctrl) |
18 (vacc) 8 (ctrl) |
14 (vacc) 10 (ctrl) |
OR 1.68 (0.7-4.05) |
||||
|
|
||||||||
|
US Navajo Apache [22]: double blind, randomized efficacy |
7vCRM |
Infants: 2,4,6, 12-15 mo; 12-23 mo: 2 doses |
Unvaccinated children/adults in study households |
2048 (vacc) 1376 (ctrl) |
29 (vacc) 37 (ctrl) |
OR 0.52 (0.31-0.87) |
15 (vacc) 23 (ctrl) |
OR 0.34 (0.16-0.75) |
|
|
||||||||
|
France [44]: effectiveness |
7vCRM |
≥ 1 dose |
Children w/AOM 6-24 mo (mean 14 mo) |
575 (vacc) 1331 (ctrl) |
59 (vacc) 178 (ctrl) |
24%* (p = 0.06) |
50 (vacc) 92 (ctrl) |
-26%* (p = 0.2) |
|
|
||||||||
|
Greece [45]: effectiveness |
7vCRM |
12-23 mo: 2 doses (13%); ≥ 24 mo: 1 dose (85%) |
13-76 mo (median 47 mo) |
285 (vacc) 582 (ctrl) |
24 (vacc) 64 (ctrl) |
36%* |
3 (vacc) 14 (ctrl) |
58%* |
|
|
||||||||
|
*Only case numbers provided in original paper; approximate % VE calculated for this table; **confidence intervals for odds rations not provided in original publication. Mo, month; NS; not significant; OR, odds ratio; VE, vaccine efficacy/effectiveness; wk, week; y, year. 7vCRM, 7-valent conjugate vaccine with CRM197 carrier. 9vCRM; 9-valent conjugate vaccine candidate with CRM197 carrier. |
||||||||
|
Hausdorff et al. BMC Pediatrics 2010 10:4 doi:10.1186/1471-2431-10-4 |
||||||||
